Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
3.045 USD | +5.73% | -2.42% | +49.75% |
May. 10 | Leerink Partners Starts Aquestive Therapeutics With Outperform Rating, $8 Price Target | MT |
May. 08 | Transcript : Aquestive Therapeutics, Inc., Q1 2024 Earnings Call, May 08, 2024 |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+49.75% | 262M | |
+42.31% | 739B | |
+32.70% | 598B | |
-5.33% | 353B | |
+17.86% | 318B | |
+4.39% | 285B | |
+16.42% | 240B | |
+9.46% | 210B | |
-5.32% | 206B | |
+7.66% | 164B |
- Stock Market
- Equities
- AQST Stock
- News Aquestive Therapeutics, Inc.
- H.C. Wainwright Raises Price Target on Aquestive Therapeutics to $9 From $7, Maintains Buy Rating